JP2003512334A - Ｇｒｂ−２ｓｈ−２ドメインの阻害剤による細胞運動性及び脈管形成の阻害 - Google Patents

Ｇｒｂ−２ｓｈ−２ドメインの阻害剤による細胞運動性及び脈管形成の阻害

Info

Publication number
JP2003512334A
JP2003512334A JP2001531405A JP2001531405A JP2003512334A JP 2003512334 A JP2003512334 A JP 2003512334A JP 2001531405 A JP2001531405 A JP 2001531405A JP 2001531405 A JP2001531405 A JP 2001531405A JP 2003512334 A JP2003512334 A JP 2003512334A
Authority
JP
Japan
Prior art keywords
group
peptide
alkyl
amino
divalent group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001531405A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003512334A5 (https=
Inventor
ピー． ボッタロ、ドナルド
エヌ． アタビー、サファイエ
ヴィ． ソリアーノ、ジーザス
イー． ブレッケンリッジ、ダイアン
ヤオ、ツー−ジュン
ガオ、ヤン
アール．ジュニア バーク、テレンス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Government of the United States of America
Original Assignee
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government of the United States of America filed Critical Government of the United States of America
Publication of JP2003512334A publication Critical patent/JP2003512334A/ja
Publication of JP2003512334A5 publication Critical patent/JP2003512334A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2001531405A 1999-10-22 2000-10-20 Ｇｒｂ−２ｓｈ−２ドメインの阻害剤による細胞運動性及び脈管形成の阻害 Pending JP2003512334A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16089999P 1999-10-22 1999-10-22
US60/160,899 1999-10-22
US22152500P 2000-07-28 2000-07-28
US60/221,525 2000-07-28
PCT/US2000/041423 WO2001028577A2 (en) 1999-10-22 2000-10-20 Inhibition of cell motility and angiogenesis by inhibitors of the grb2 sh2-domain

Publications (2)

Publication Number Publication Date
JP2003512334A true JP2003512334A (ja) 2003-04-02
JP2003512334A5 JP2003512334A5 (https=) 2007-12-20

Family

ID=26857321

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001531405A Pending JP2003512334A (ja) 1999-10-22 2000-10-20 Ｇｒｂ−２ｓｈ−２ドメインの阻害剤による細胞運動性及び脈管形成の阻害

Country Status (9)

Country Link
US (1) US7132392B1 (https=)
EP (1) EP1223959B1 (https=)
JP (1) JP2003512334A (https=)
AT (1) ATE362767T1 (https=)
AU (1) AU780697B2 (https=)
CA (1) CA2387922C (https=)
DE (1) DE60034959T2 (https=)
ES (1) ES2287048T3 (https=)
WO (1) WO2001028577A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7871981B2 (en) * 1999-10-22 2011-01-18 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of cell motility, angiogenesis, and metastasis
WO2004003005A2 (en) * 2002-06-28 2004-01-08 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Sh2 domain binding inhibitors
US7425537B2 (en) 2000-08-22 2008-09-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services SH2 domain binding inhibitors
US20040253294A1 (en) * 2001-07-18 2004-12-16 Yasuhiko Tabata Sustained release hgf hydrogel preparations
US20080081841A1 (en) * 2003-03-20 2008-04-03 Badache Ali Materials and Methods for Modulating Cell Motility
EP2350656B1 (en) * 2008-10-30 2015-01-07 The Translational Genomics Research Institute Methods and kits to identify invasive glioblastoma
CN110981938A (zh) * 2019-12-10 2020-04-10 中山大学·深圳 靶向grb2 sh2结合域的抗肿瘤多肽及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997008193A1 (en) * 1995-08-17 1997-03-06 Novartis Ag Acylated oligopeptide derivatives having cell signal inhibiting activity

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3906031A (en) 1971-03-15 1975-09-16 Research Corp Novel 9-fluorenylmethoxycarbonyl compounds
US4394519A (en) 1982-01-19 1983-07-19 Research Corporation Amino acid blocking agents
US4879398A (en) 1987-12-31 1989-11-07 Monsanto Company Process for producing 2,6-disubstituted tyrosine
US5296608A (en) 1988-04-25 1994-03-22 Hoffman-La Roche Inc. Intermediates for analogs of tyrosine sulfate or tyrosine phosphate containing peptides
US5182263A (en) 1988-04-25 1993-01-26 Hoffmann-La Roche Inc. Analogs of tyrosine sulfate or tyrosine phosphate containing peptides
US5272268A (en) 1990-06-28 1993-12-21 Shionogi & Co., Ltd. Dipeptide derivatives
US5679842A (en) 1990-08-17 1997-10-21 Hoechst Aktiengesellschaft Process for the preparation of aminomethanephosphonic acid and aminomethylphosphinic acids
AU657498B2 (en) 1990-12-14 1995-03-16 Novartis Ag Biphenylyl compounds
DE4115468A1 (de) 1991-05-11 1992-11-12 Behringwerke Ag Amidinophenylalaninderivate, verfahren zu deren herstellung, deren verwendung und diese enthaltende mittel als antikoagulantien
US5200546A (en) 1991-09-30 1993-04-06 The United States Of America As Represented By The Department Of Health And Human Services Phosphonoalkyl phenylalanine compounds suitably protected for use in peptide synthesis
US5587372A (en) 1991-12-12 1996-12-24 Roussel Uclaf Cephalosporins
TW399041B (en) 1992-09-09 2000-07-21 Hoechst Ag Substituted cyclohexane derivatives, the preparation and the use for treating diseases
AU5136093A (en) 1992-09-25 1994-04-26 Warner-Lambert Company Peptide antagonists of sh2 binding and therapeutic uses thereof
US5981569A (en) 1992-11-13 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease
US5792771A (en) 1992-11-13 1998-08-11 Sugen, Inc. Quinazoline compounds and compositions thereof for the treatment of disease
US5712395A (en) 1992-11-13 1998-01-27 Yissum Research Development Corp. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
EP0672059A1 (en) 1992-11-18 1995-09-20 The Du Pont Merck Pharmaceutical Company CYCLIC COMPOUNDS LINKED BY A HETEROCYCLIC RING USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa
GB9302331D0 (en) 1993-02-05 1993-03-24 Smithkline Beecham Plc Process
PL179628B1 (pl) 1993-06-30 2000-10-31 Pharmacia Spa Peptydy b ed ace inhibitorami m itogenezy i m otogenezy, sp o só b ich wytwarzania, i zawierajacy je srodek farm aceutyczny PL PL PL PL PL PL
US5491253A (en) 1993-10-22 1996-02-13 Abbott Laboratories Process for the preparation of a substituted 2,5-diamino-3-hydroxyhexane
ES2157994T3 (es) 1993-10-25 2001-09-01 Parke Davis & Co Inhibidores tetra y pentapeptidos sustituidos de la proteina farnesiltransferasa.
US5576323A (en) 1993-12-03 1996-11-19 Eli Lilly And Company Excitatory amino acid receptor antagonists
WO1995024190A2 (en) 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
US6037134A (en) 1994-03-07 2000-03-14 New York University Medical Center Methods that detect compounds that disrupt receptor tyrosine kinase/GRB-7 complexes
US5580979A (en) 1994-03-15 1996-12-03 Trustees Of Tufts University Phosphotyrosine peptidomimetics for inhibiting SH2 domain interactions
US5707624A (en) 1994-06-03 1998-01-13 The Regents Of The University Of Michigan Treatment of Kaposi's sarcoma by inhibition of scatter factor
US5786454A (en) 1994-09-16 1998-07-28 Washington University School Of Medicine Modified SH2 domains
WO1996023813A1 (en) 1995-02-01 1996-08-08 Affymax Technologies N.V. Peptides and compounds that bind to sh2 domains
US5756817C1 (en) 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
US5710129A (en) 1995-02-23 1998-01-20 Ariad Pharmaceuticals, Inc. Inhibitors of SH2-mediated processes
US5688992A (en) 1995-03-31 1997-11-18 The United States Of America As Represented By The Department Of Health And Human Services O-malonyltryrosyl compounds, O-malonyltryrosyl compound-containing peptides, and use thereof
US5646036A (en) 1995-06-02 1997-07-08 Genentech, Inc. Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US5612370A (en) 1995-06-07 1997-03-18 Bristol-Myers Squibb Company Phenylglycine and phenylalaninen amido benzopyran derivatives
WO1996040629A1 (en) 1995-06-07 1996-12-19 Sugen, Inc. Tyrphostin-like compounds for the treatment of cell proliferative disorders or cell differentiation disorders
KR19990022369A (ko) 1995-06-07 1999-03-25 스테판 이반스-프레크 어뎁터 단백질/티로신 카이나제 상호작용을 방해하는 조성물과그 방법
US5798374A (en) 1995-06-07 1998-08-25 Sugen Inc. Methods of inhibiting phosphatase activity and treatment of disorders associated therewith
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5710173A (en) 1995-06-07 1998-01-20 Sugen, Inc. Thienyl compounds for inhibition of cell proliferative disorders
US5965558A (en) 1995-06-19 1999-10-12 Ontogen Corporation Modulators of proteins with phosphotyrosine recognition units
US5753687A (en) 1995-06-19 1998-05-19 Ontogen Corporation Modulators of proteins with phosphotryrosine recognition units
IT1282022B1 (it) 1995-07-06 1998-03-06 Mini Ricerca Scient Tecnolog Procedimento per la produzione di carbammati aromatici
US5958957A (en) 1996-04-19 1999-09-28 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
US6228986B1 (en) 1998-04-13 2001-05-08 Ortho-Mcneil Pharmaceutical, Inc. Solid-phase synthesis of novel 14-membered macroycles for high throughput screening
US6307090B1 (en) * 1999-01-22 2001-10-23 The United States Of America As Represented By The Department Of Health And Human Services Acylated oligopeptide derivatives having cell signal inhibiting activity
CA2368733C (en) 1999-03-23 2014-10-07 Terrence R. Burke, Jr. Phenylalanine derivatives
WO2000073326A2 (en) 1999-06-02 2000-12-07 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Redox-stable, non-phosphorylated cyclic peptide inhibitors of sh2 domain binding to target protein, conjugates thereof, compositions and methods of synthesis and use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997008193A1 (en) * 1995-08-17 1997-03-06 Novartis Ag Acylated oligopeptide derivatives having cell signal inhibiting activity

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN5002020389, ＧＡＹ ＢＲＩＧＩＴＴＥ, ＪＯＵＲＮＡＬ ＯＦ ＢＩＯＬＯＧＩＣＡＬ ＣＨＥＭＩＳＴＲＹ, 19990813, Ｖｏｌ．２７４ Ｎｏ．３３, ｐｐ．２３３１１−２３３１５ *
JPN5002020390, ＺＨＵ−ＪＵＮ ＹＡＯ, ＪＯＵＲＮＡＬ ＯＦ ＭＥＤＩＣＩＮＡＬ ＣＨＥＭＩＳＴＲＹ, 1999, Ｖｏｌ．４２ Ｎｏ．１, ｐｐ．２５−３５, US, ＡＭＥＲＩＣＡＮ ＣＨＥＭＩＣＡＬ ＳＯＣＩＥＴＹ *
JPN6010055560, ＧＡＹ ＢＲＩＧＩＴＴＥ, ＩＮＴ． Ｊ． ＣＡＮＣＥＲ, 199908, Ｖｏｌ．８３, ｐｐ．２３５−２４１ *

Also Published As

Publication number Publication date
CA2387922C (en) 2011-12-06
DE60034959D1 (de) 2007-07-05
CA2387922A1 (en) 2001-04-26
WO2001028577A2 (en) 2001-04-26
WO2001028577A3 (en) 2001-12-13
ES2287048T3 (es) 2007-12-16
DE60034959T2 (de) 2008-01-17
AU780697B2 (en) 2005-04-14
EP1223959B1 (en) 2007-05-23
AU2916601A (en) 2001-04-30
US7132392B1 (en) 2006-11-07
EP1223959A2 (en) 2002-07-24
ATE362767T1 (de) 2007-06-15

Similar Documents

Publication Publication Date Title
JP6641356B2 (ja) 疾患の予防及び治療のための方法及び組成物
JP2003522107A (ja) 骨成長および毛成長を刺激するためのプロテアソーム活性のインヒビター
EP2552470B1 (en) Peptides for promoting angiogenesis and an use thereof
JPH09500087A (ja) カルパイン活性の増大に関連した健康障害の抑制及び処置におけるカルパイン阻害剤の使用法
JP2002512038A (ja) 被験体における腫瘍の浸潤または蔓延の阻害法
US6194380B1 (en) Agents for promoting bone formation
EP3054942B1 (en) Treatments for proliferative vitreoretinopathy
JP2003512334A (ja) Ｇｒｂ−２ｓｈ−２ドメインの阻害剤による細胞運動性及び脈管形成の阻害
JP2005506295A (ja) 細胞間連絡促進化合物の新規医薬使用
CA2288178A1 (en) Piperazine derivatives for treating bone deficit conditions
RU2260597C2 (ru) Олигопептиды
EP3299382B1 (en) Oligopeptide having proinflammatory cytokine secretion-inhibiting activity
US9249185B2 (en) Peptides for promoting angiogenesis and an use thereof
RU2262509C2 (ru) Низкомолекулярные производные пептидов как ингибиторы взаимодействия ламинина/нидогена
US6977241B2 (en) SH2 domain binding inhibitors
US7871981B2 (en) Inhibition of cell motility, angiogenesis, and metastasis
CA2582224A1 (en) Compositions and methods for modulating tissue regeneration and chemotactic responses
JP3750983B2 (ja) 骨疾患の治療剤
US20240382559A1 (en) Pharmaceutical composition comprising kai1 polypeptide for inhibition of hepatic fibrosis and use thereof
JP2005504768A (ja) アポトーシスに関連した疾患を治療するための方法および組成物
JP2005213159A (ja) 血管新生阻害剤及び血管退縮剤
Guo CD105 expression and its effects on TGF-β signalling, angiogenesis and cell behaviour
HK1052015A (en) Oligopeptides
WO2007013147A1 (ja) 血管新生阻害剤及び血管退縮剤
JPWO2001072321A1 (ja) γ−セクレターゼ様プロテアーゼの阻害剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071018

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071018

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101005

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110412